A detailed history of Trust CO Of Vermont transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Trust CO Of Vermont holds 1,553 shares of LCTX stock, worth $993. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,553
Holding current value
$993
% of portfolio
0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 16, 2024

BUY
$0.8 - $1.12 $1,242 - $1,739
1,553 New
1,553 $1,000
Q3 2022

Oct 24, 2022

BUY
$1.13 - $1.77 $2,349 - $3,679
2,079 New
2,079 $2,000

Others Institutions Holding LCTX

About Lineage Cell Therapeutics, Inc.


  • Ticker LCTX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 169,755,008
  • Market Cap $109M
  • Description
  • Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...
More about LCTX
Track This Portfolio

Track Trust CO Of Vermont Portfolio

Follow Trust CO Of Vermont and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trust CO Of Vermont, based on Form 13F filings with the SEC.

News

Stay updated on Trust CO Of Vermont with notifications on news.